HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation

Maladie de Parkinson et DMLA : y a-t-il un lien ?

Abstract : Neovascular age-related macular degeneration (nAMD) remains a major cause of visual impairment, despite the continuous repeated intravitreal administration of anti-VEGF therapies that puts a considerable burden on patients, ophthalmologists and health care systems. A retrospective cohort of several million of patients in US found that L-DOPA treated parkinsons disease (PD) patients have a significantly delayed age of onset for nAMD. Using MPTP-induced PD- and laser-induced nAMD- mouse models in combination with the standard PD treatment of L-DOPA / DOPA-decarboxylase inhibitor, we here demonstrate that an L-DOPA treatment-induced increase of dopamine receptor 2 (DR2) signaling, and not the PD itself, is likely responsible for the inhibition of choroidal neovascularization. While explaining an intriguing epidemiological observation, our findings show that systemic DR2 agonists might constitute a much sought after therapy to reduce the need for anti-VEGF therapy in nAMD patients.
Complete list of metadata

Contributor : Abes Star :  Contact
Submitted on : Wednesday, January 19, 2022 - 12:13:20 PM
Last modification on : Thursday, January 20, 2022 - 3:39:43 AM
Long-term archiving on: : Wednesday, April 20, 2022 - 6:32:34 PM


Version validated by the jury (STAR)


  • HAL Id : tel-03534234, version 1


Thibaud Mathis. Maladie de Parkinson et DMLA : y a-t-il un lien ?. Biologie moléculaire. Université de Lyon, 2020. Français. ⟨NNT : 2020LYSE1329⟩. ⟨tel-03534234⟩



Record views


Files downloads